Skip to main content

Advertisement

SpringerLink
Log in

Valdoxan in the Treatment of Depression in Neurological Practice: Results of the Russian Multicenter Naturalistic Study “Resonance”

  • Published:
Neuroscience and Behavioral Physiology Aims and scope Submit manuscript

The efficacy and tolerance of Valdoxan (agomelatine) in mild and moderate depression due to neurological diseases (cerebrovascular pathology, neurocirculatory dystonia, chronic pain) were studied. A total of 227 patients aged 18–70 (mean 46.0 ± 11.3) years were studied, including 21.66 % men and 76.53 % women. Patients received Valdoxan for six months. After courses, most patients (81.20 %) showed elimination of depression symptomatology, with regression of fatigue, improvements in ability to work (on specific tests), and normalization of the coefficient of mental stability.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. O. V. Vorob’eva, “Clinical characteristics of depression in general medical practice (results of the “Kompas” program),” Consilium, 6, No. 2, 154–158(2004).

    Google Scholar 

  2. G. M. Goodwin, Remsley, S. Rembry, et al., “Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial,” J. Clin. Psychiatry, 70, 1128–1137 (2009).

  3. D. Harwood, K. Hawton, T. Hope, and R. Jacob, “Psychiatric disorder and personality factors associated with suicide in older people: a descriptive and case-control study,” Int. J. Ger. Psychiatry, 16, 155–165 (2001).

    Article  CAS  Google Scholar 

  4. H. Loo, A. Hale, and H. D’Haenen, “Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study,” Int. Clin. Psychopharmacol., 17, 239–247 (2002).

    Article  PubMed  CAS  Google Scholar 

  5. L. San and B. Arranz, “Agomelatine: a novel mechanism of depression action involving the melatonergic and the serotonergic system,” Eur. Psychiatry, 23, 396–402 (2008).

    Article  PubMed  Google Scholar 

  6. D. J. Stein, A. A. Ahokas, and C. de Bodinat, “Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebocontrolled study,” J. Clin. Psychopharmacol., 28, 561–566 (2008).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. I. M. Sechenov First Moscow State Medical University, Moscow, Russia

    O. V. Vorob’eva

Authors
  1. O. V. Vorob’eva
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to O. V. Vorob’eva.

Additional information

Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 112, No. 9, Iss. I, pp. 47–51, September, 2012.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vorob’eva, O.V. Valdoxan in the Treatment of Depression in Neurological Practice: Results of the Russian Multicenter Naturalistic Study “Resonance”. Neurosci Behav Physi 43, 1126–1131 (2013). https://doi.org/10.1007/s11055-013-9860-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11055-013-9860-7

Keywords

Search

Navigation